Chroma Medicine, an innovative leader in the field of genomic therapies, has successfully raised a remarkable $260 million in its latest funding round. This significant capital infusion will catalyze the company鈥檚 mission to develop a groundbreaking class of single-dose genomic medicines that leverage the power of epigenetics鈥攖he natural mechanism that regulates gene activity without altering the DNA sequence itself. By harnessing this innate biological process, Chroma Medicine is poised to revolutionize treatments for a variety of diseases, effectively addressing medical conditions previously deemed difficult to treat with conventional therapies. The new funds will enable the company to accelerate its research and development efforts, furthering the creation of therapeutics that provide unprecedented control of gene expression. As Chroma Medicine continues to build on the pioneering work of leading genomic medicine experts, it sets its sights on transforming the landscape of precision medicine and enhancing patient outcomes. The company remains committed to upholding the highest standards of integrity and professionalism, reminding all potential candidates that vigilance is essential in avoiding fraudulent recruitment scams associated with job offers in the industry. For those interested in exploring career opportunities at Chroma Medicine, we encourage you to visit the Join Us page on our website for legitimate openings and company updates. With this latest funding round, Chroma Medicine is not just taking a significant step forward鈥攊t's paving the way for the future of genomic medicine.
Chroma Medicine Secures $260 Million Investment to Pave the Way for Revolutionary Single-Dose Genomic Medicines
Recently funded 路 $260.0MHealthcare
Get the full Chroma Medicine company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
